Alnylam Pharmaceuticals, Inc. (ALNY)
| Market Cap | 41.16B +40.5% |
| Revenue (ttm) | 3.71B +65.2% |
| Net Income | 313.75M |
| EPS | 2.33 |
| Shares Out | 133.43M |
| PE Ratio | 132.41 |
| Forward PE | 46.69 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,093,427 |
| Open | 303.87 |
| Previous Close | 305.54 |
| Day's Range | 303.70 - 314.74 |
| 52-Week Range | 245.96 - 495.55 |
| Beta | 0.38 |
| Analysts | Strong Buy |
| Price Target | 471.00 (+52.67%) |
| Earnings Date | Apr 30, 2026 |
About ALNY
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amylo... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for ALNY stock is "Strong Buy." The 12-month stock price target is $471.0, which is an increase of 52.67% from the latest price.
News
Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter endi...
New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new clinical and real-world data from its cardiovascular (CV) po...
Alnylam Pharmaceuticals Transcript: Status update
AMVUTTRA has rapidly gained market share in ATTR cardiomyopathy, driving strong revenue growth and broad physician adoption. Clinical data support its differentiated profile, while strategic investments in diagnosis, access, and innovation position it for sustained leadership and expansion globally.
Viz.ai Partners with Alnylam Pharmaceuticals to Advance Earlier Identification and Care Coordination in Cardiac Amyloidosis
SAN FRANCISCO--(BUSINESS WIRE)-- #ai--Viz.ai, the leader in AI-powered disease detection and care coordination, today announced a partnership with Alnylam Pharmaceuticals, the leading RNAi therapeutic...
Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier recogn...
How Alnylam Stock Weathers Market Shocks
Investing in equities involves accepting volatility as the cost of long-term compounding. In 15 significant systemic shocks during which Alnylam Pharmaceuticals (ALNY) was traded, the stock experience...
Alnylam to Webcast TTR Investor Webinar
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the In...
Tenaya Therapeutics Stock Jumps After New Alnylam Deal
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) shares are up on Thursday, reflecting a positive market response to a research collaboration agreement with Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY).
Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments
Tenaya Therapeutics said on Thursday it has signed a research deal with Alnylam Pharmaceuticals worth up to $1.13 billion to develop treatments for heart diseases.
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
Agreement Combines Tenaya's Expertise in Identification and Validation of Genetic Heart Disease Targets with Alnylam's Ability to Deliver Transformational Therapeutics Tenaya to Receive Up to $10 Mill...
Alnylam Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
AMVUTTRA's growth is fueled by rising treatment rates and strong market access, with a focus on expanding first-line share and robust revenue guidance through 2030. The pipeline features next-gen TTR therapies, cardiometabolic assets, and bleeding disorder programs, supported by a 30% R&D reinvestment strategy and selective external innovation.
Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the TD Cowen ...
Alnylam Pharmaceuticals Earnings Call Transcript: Q4 2025
Blockbuster AMVUTTRA launch drove 81% revenue growth and GAAP profitability in 2025, with strong TTR and rare disease franchise momentum. 2026 guidance projects 71% revenue growth, continued pipeline expansion, and disciplined investment, while pricing and competitive dynamics are factored into outlook.
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and ful...
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and...
Alnylam Lays Out 2030 Vision, Bets On TTR Leadership And Pipeline Scale
Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) announced a new five-year roadmap, "Alnylam 2030," on Sunday, outlining the company's focus on scaling its operations.
Alnylam Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
Six approved RNAi medicines and a robust pipeline drove 2025 revenues to nearly $3 billion, with Amvuttra leading TTR franchise growth. Ambitious 2030 goals target global TTR leadership, 10+ tissue types, and over $10 billion in annual revenue.
Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its new five-year strategy, “Alnylam 2030,” focused on scaling t...
Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate ...
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.
Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing faci...
Is Alnylam Entering A Corrective Phase After A Strong Run?
Alnylam (NASDAQ: ALNY) has corrected by roughly 13% over the past couple of weeks. To understand why this pullback is unfolding now, it is important to examine the stock's structure through the lens o...
Walmart was too late for a Nasdaq-100 spot — but these 6 stocks made the cut
Six companies will join the Nasdaq-100 later this month — but not Walmart, which switched its listing away from the New York Stock Exchange too late to qualify for a spot in the tech-heavy index.
Eight stock picks to play one of the healthiest corners of the market
The healthcare sector of the U.S. stock market as a whole is cheaply priced, which can make it attractive to investors concerned that the S&P 500 has gotten too expensive several years into a bull mar...